U.S. markets close in 4 hours 41 minutes
  • S&P 500

    4,409.43
    -13.72 (-0.31%)
     
  • Dow 30

    34,884.59
    -231.81 (-0.66%)
     
  • Nasdaq

    14,768.49
    +7.20 (+0.05%)
     
  • Russell 2000

    2,215.10
    -8.48 (-0.38%)
     
  • Crude Oil

    69.16
    -1.40 (-1.98%)
     
  • Gold

    1,812.30
    -1.80 (-0.10%)
     
  • Silver

    25.46
    -0.12 (-0.48%)
     
  • EUR/USD

    1.1839
    -0.0030 (-0.25%)
     
  • 10-Yr Bond

    1.2000
    +0.0240 (+2.04%)
     
  • GBP/USD

    1.3905
    -0.0010 (-0.07%)
     
  • USD/JPY

    109.6050
    +0.5550 (+0.51%)
     
  • BTC-USD

    39,329.41
    +1,166.79 (+3.06%)
     
  • CMC Crypto 200

    970.06
    +43.29 (+4.67%)
     
  • FTSE 100

    7,127.02
    +21.30 (+0.30%)
     
  • Nikkei 225

    27,584.08
    -57.75 (-0.21%)
     

Acetaminophen (Paracetamol) Market Report to 2031: Visiongain Research Inc.

·6 min read

Visiongain has published a new report on Acetaminophen (Paracetamol) Market Report to 2031: Forecasts by Type (Veterinary Drug Grade and Acetaminophen Grade), By Form (Tablet, Capsule, Liquid Suspension, and Powder), By Application (Pharmaceuticals, Dye Industries, and Chemical Industries) PLUS COVID-19 Recovery Scenarios.

COVID-19 Impact on Acetaminophen (Paracetamol) Market
COVID-19 pandemic has poised an unprecedented sanitary risk. Drugs that may decrease the brutality of the infection and decrease the high mortality rate. To this end, several medicines have been repurposed, including paracetamol. It can help to relieve patients with these symptoms; however, it is not a cure against COVID-19.

Download Exclusive Sample of Report @ https://www.visiongain.com/report/paracetamol-market/#download_sampe_div

Paracetamol made news on the headlines in the initial phase of COVID-19 for the reason that some government bodies and organizations, including the World Health Organization, France, and the United Kingdom encouraged people with COVID-19 to take paracetamol instead of ibuprofen. Moreover, the pandemic has increased the demand for pharmaceutical drugs but also disturbed the entire pharmaceutical supply chain. Pharmacies have been running short of Acetaminophen and some shops have been limiting the sales of these drugs. Although, pharmaceutical companies have improved their production capacity significantly to keep pace with the growing demand for the drugs. In turn, it is projected to have a positive impact on the target industry growth.

Market Drivers

Rising Prevalence of Chronic Diseases
Rising incidence and prevalence of cardiovascular diseases, osteoarthritis disorder, and multiple cancer are expected to be major driving factors for the growth of the acetaminophen (paracetamol) market during the forecast period. According to Cancer Australia estimates, around 1,405 new cases of brain cancer are expected in 2017. Furthermore, as per the World Health Organization (WHO), the common reason for death is cardiovascular diseases (CVD) across the world. Also, as per the Centers for Disease Control and Prevention (CDC), nearly 1.70 million people die from a chronic disease every year in the USA. Although chronic diseases are the major reason for death for men and women alike because women face unique health issues. Around 37% of women suffer from chronic diseases, compared to 30% of men. Moreover, according to the World Health Organization (WHO) estimates, by 2050, around 130 million people are expected to suffer from osteoarthritis worldwide. Thereby, the rising high prevalence of cardiovascular diseases and other chronic disorders demands proper treatment management to maximize patient outcomes. In turn, it is projected to attain substantial growth for the acetaminophen (paracetamol) market in the given time frame.

Growing Demand for Pain Management Drugs

There is an availability of sophisticated treatments and developments in technologies that have augmented lifespan universally, which has upsurge the elderly population. As old people are exceedingly prone to suffer from various kinds of pain, due to many reasons such as a growth in the prevalence of acute and chronic diseases such as stroke, heart disease, type II diabetes, and cancer, which pushes the pain management drug demand. According to the UN Population Division statistics, in 2019, the total proportion of people above 65 years has raised from 703 million in 2019 and is expected to be 1.5 billion by 2050, worldwide.

Market Opportunities

Rapidly Increasing Health Care Expenditure
Healthcare spending has increased drastically in the U.S. in the past few decades. As per the Journal of the American Medical Association (JAMA), healthcare expenditure in the U.S. upsurge near a trillion dollars between 1996 and 2015. The association told that healthcare expenditure in the U.S. during 2017 was around $3.5 trillion, i. e, $11,000 per person. These expenditures are projected to be $6 trillion—approximately $17,000 per person by 2027.

Get Detailed TOC @ https://www.visiongain.com/report/paracetamol-market/#download_sampe_div

How the Acetaminophen (paracetamol) Market report helps you
In summary, report provides you with the following knowledge:

  • Revenue forecasts to 2031 for Paracetamol Market, with forecasts for Product Type, Form and Application, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

  • Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Acetaminophen (paracetamol) market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.

  • Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Acetaminophen (paracetamol) Market.

Competitive Landscape

Key players operating in the global Acetaminophen (Paracetamol) market are Aknil biotech, Mallinckrodt, Captab biotech, Farmson, M.M. Pharma and Genesis Biotech, Granules India, SKPL, Glaxo SmithKline Pharmaceuticals Ltd, Atabay, Arika Healthcare, and Sino Chemical.

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

To access the data contained in this document please email contactus@visiongain.com

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the Acetaminophen Market and leading companies. Here you will find data, trends and predictions. Please order our report now.

Find more Visiongain research reports on Therapeutic Drugs Sector click on the following links:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

About Visiongain

Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.

Contact:

Sara Peerun
Commercial Director
Visiongain Inc.
Tel: + 44 207 549 9987
USA Tel: 00 1 718 682 4567
EU Tel: 00 353 1 695 0006
Email: sara.peerun@visiongain.com
Web: https://www.visiongain.com/
Follow Us: LinkedIn | Twitter

-

SOURCE Visiongain Limited.